Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Peter Spreyer is active.

Publication


Featured researches published by Peter Spreyer.


European Journal of Pharmacology | 2003

Pharmacological sensitivity and gene expression analysis of the tibial nerve injury model of neuropathic pain

Heiko A. Hofmann; Jean De Vry; Angela Siegling; Peter Spreyer; Dirk Denzer

The tibial nerve injury model is a novel, surgically uncomplicated, rat model of neuropathic pain based on a unilateral transection (neurotomy) of the tibial branch of the sciatic nerve. The aim of the present study was to describe some behavioral and molecular features of the model, and to test its sensitivity to a number of drugs which are currently used for the treatment of neuropathic pain. The model was characterized by a pronounced mechanical allodynia which was present in all subjects and a less robust thermal hyperalgesia. Mechanical allodynia developed within 2 weeks post-surgery and was reliably present for at least 9 weeks. Neurotomized rats showed no autotomy and their body weight developed normally. Gene expression in ipsilateral L5 dorsal root ganglia, analyzed by quantitative polymerase chain reaction (PCR), showed a pronounced up-regulation of galanin and vasointestinal peptide (VIP). This up-regulation developed rapidly (within 1 to 2 days following neurotomy) and remained present for at least 12 days. On the other hand, expression of calcitonin gene-related peptide (CGRP) and substance P mRNA was down-regulated 12 days following neurotomy. Mechanical allodynia was completely reversed by morphine [minimal effective dose (MED): 8 mg/kg, i.p.] and partially reversed by carbamazepine (MED: 64 mg/kg, i.p.), baclofen (MED: 3 mg/kg, i.p.) and amitriptyline (trend for efficacy at 32 mg/kg, i.p.), but not by gabapentin (50-100 mg/kg, i.p.). The finding that the tibial nerve injury model shows a robust and persistent mechanical allodynia which is sensitive to a number of established analgesics, as well as a gene expression profile which is compatible with that obtained in other models of neuropathic pain, further supports its validity as a reliable and surgically uncomplicated model for the study of neuropathic pain.


European Journal of Pharmacology | 2001

Metabotropic glutamate mGlu1 receptor mRNA expression in dorsal root ganglia of rats after peripheral nerve injury.

Heiko A. Hofmann; Angela Siegling; Dirk Denzer; Peter Spreyer; Jean De Vry

Although cerebral and spinal metabotropic glutamate mGlu(1) receptors are thought to be involved in nociception and in the development/maintenance of chronic pain, it is still unclear to what extent mGlu(1) receptors are present in the dorsal root ganglia of peripheral sensory afferents, and whether their expression is affected during development of chronic pain. It was found in the present study that mGlu(1) receptor messenger RNA (mRNA) is present in rat L5 dorsal root ganglia and that it is strongly downregulated after unilateral axotomy of the tibial branch of the sciatic nerve, a model of chronic neuropathic pain. However, as sham-operated animals showed a similar downregulation, it is suggested that peripheral tissue damage is sufficient to result in a reduction of peripheral mGlu(1) receptor expression.


Archive | 1993

Molecular Biology of Calcium Channels

Peter Spreyer; J. K. Franz; A. Eller; Peter Rae; Axel Dr. Unterbeck

Voltage-operated calcium channels (VOCCs) are membrane-spanning multisubunit protein complexes which are the major element controlling calcium entry from the extracellular space into the cytoplasm of excitable cells. VOCCs are predominantly expressed in neuronal and endocrine cells, and in cardiac, smooth, and skeletal muscle.


Archive | 1998

Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases

Joachim Mittendorf; Jürgen Dr. Dressel; Michael Matzke; Jörg Keldenich; Klaus-Helmut Mohrs; Siegfried Raddatz; Jürgen Franz; Peter Spreyer; Verena Vöhringer; Joachim Schuhmacher; Michael-Harold Rock; Ervin Horvath; Arno Friedl; Frank Mauler; Jean De Vry; Reinhard Jork


Archive | 2001

Use of known agonists of the central cannabinoid receptor CB1

Joachim Mittendorf; Jürgen Dr. Dressel; Michael Matzke; Jürgen Franz; Peter Spreyer; Verena Vöhringer; Joachim Schuhmacher; Arno Friedl; Ervin Horvath; Frank Mauler; Jean-Marie-Viktor De Vry; Reinhard Jork


Bioorganic & Medicinal Chemistry Letters | 2004

Discovery and optimization of 2-aryl oxazolo-pyrimidines as adenosine kinase inhibitors using liquid phase parallel synthesis.

M Bauser; G Delapierre; M Hauswald; T Flessner; D D'Urso; A Hermann; B Beyreuther; J. De Vry; Peter Spreyer; E Reissmüller; Heinrich Meier


Archive | 1999

Aryl sulphonamides and analogues

Joachim Mittendorf; Jürgen Dr. Dressel; Michael Matzke; Jörg Keldenich; Frank Mauler; Jean-Marie-Victor de Vry; Jürgen Franz; Peter Spreyer; Verena Vöhringer; Joachim Schumacher; Michael-Harold Rock; Ervin Horvath; Arno Friedl; Klaus-Helmut Mohrs; Siegfried Raddatz; Reinhard Jork


Archive | 1993

Human neuronal beta subunits of voltage-operated calcium channels and the use thereof

Peter Spreyer; Axel Unterbeck


Archive | 1999

Aryl sulphonamide amino acid esters and analogues

Joachim Mittendorf; Jürgen Dr. Dressel; Michael Matzke; Jörg Keldenich; Frank Mauler; Jean-Marie-Viktor De Vry; Jürgen Franz; Peter Spreyer; Verena Vöhringer; Joachim Schumacher; Michael-Harold Rock; Ervin Horvath; Arno Friedl


Archive | 1993

Human neuronal beta-subunits of voltage-dependent calcium channels and use of the same

Peter Spreyer; Axel Dr. C

Collaboration


Dive into the Peter Spreyer's collaboration.

Researchain Logo
Decentralizing Knowledge